SCHEMBL4065146

SCHEMBL4065146

CC(=O)OCc1cc(C)cc(C)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.39
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADORA2A P29274 1/20 0.36
ADORA1 P30542 1/20 0.36
MAPK1 P28482 1/20 0.36
LMNA P02545 2/20 0.35
NOS3 P29474 1/20 0.35
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
MAPT P10636 1/20 0.35
CYP3A4 P08684 1/20 0.35
KMT2A Q03164 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA4 P43681 1/20 0.35
HTT P42858 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6549108 0.83 KMT2A (0.40) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19
SCHEMBL17932863 0.81 ALDH1A1 (0.40) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19
SCHEMBL10139066 0.80 ALDH1A1 (0.39) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19
SCHEMBL12574416 0.80 ALDH1A1 (0.39) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19
SCHEMBL17544478 0.79 KDM4E (0.44) ALDH1A1KDM4EMAPK1LMNAKMT2A
SCHEMBL6797990 0.79 KDM4E (0.39) ALDH1A1HSD17B10KDM4EMAPTKMT2A
Formic Acid SCHEMBL38650773 0.78 PSD (0.34) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19
SCHEMBL22507072 0.76 ALDH1A1 (0.40) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19
SCHEMBL11240594 0.76 MAPT (0.42) ALDH1A1ADORA2AADORA1MAPK1NOS3
SCHEMBL4064980 0.76 ALDH1A1 (0.52) ALDH1A1HSD17B10KDM4ECYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317445-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-03-11 EP disclosed
US-7396840-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2008-07-08 US disclosed
US-7084155-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2006-08-01 US disclosed
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-06-15 US disclosed
US-6864265-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2005-03-08 US disclosed
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-04 US disclosed
CN-1457339-A Chemokine receptor binding heterocyclic compounds ANORMED INC (CA) 2003-11-19 CN disclosed
EP-1317445-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-01-23 US disclosed
WO-2002022600-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 ALDH1A1 1755/4885HSD17B10 2388/4885KDM4E 4709/4885
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds CXCR4, CCR5, CXCR3 ALDH1A1 2001/4885HSD17B10 3421/4885KDM4E 4665/4885
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 ALDH1A1 1755/4885HSD17B10 2388/4885KDM4E 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.